A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
Glucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences confound comparison of results from different glucose...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2018-08-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4903 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849737505642905600 |
|---|---|
| author | Oppel B.W. Greeff Jacob John van Tonder Kershlin Naidu Alicia McMaster Alet van Tonder Rashem Mothilal |
| author_facet | Oppel B.W. Greeff Jacob John van Tonder Kershlin Naidu Alicia McMaster Alet van Tonder Rashem Mothilal |
| author_sort | Oppel B.W. Greeff |
| collection | DOAJ |
| description | Glucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences confound comparison of results from different glucose clamp studies. The first part of this series on glucose clamp studies discussed practical tips for the interpretation of glucose clamp studies. The second part of the series compares the PK/PD profiles of longer-acting basal analogue insulins, insulin degludec (IDeg) and insulin glargine U300 (Gla-300). The patient populations for glucose clamp studies with these analogue insulins differ, and therefore direct comparison of the data is not always possible. The maximum duration of action of IDeg is reported as 42 h and that of Gla-300 as 36 h, translating to 24 h coverage. The plasma insulin concentration of IDeg is 56 times that of Gla-300. Results from phase III clinical trials for these analogue insulins confirm the predictability and low within-subject variability observed in glucose clamp studies. Insight into the PK/PD profiles of longer-acting basal analogue insulins allows the treating physician to utilise these characteristics to optimise the treatment of their patients with diabetes. |
| format | Article |
| id | doaj-art-6cd049cdc37e4ae999e4b43232ef43b7 |
| institution | DOAJ |
| issn | 2078-6190 2078-6204 |
| language | English |
| publishDate | 2018-08-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj-art-6cd049cdc37e4ae999e4b43232ef43b72025-08-20T03:06:53ZengAOSISSouth African Family Practice2078-61902078-62042018-08-0160471210.4102/safp.v60i4.49033879A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300Oppel B.W. Greeff0Jacob John van Tonder1Kershlin Naidu2Alicia McMaster3Alet van Tonder4Rashem Mothilal5University of PretoriaTriclinium Clinical Development (Pty) LtdChris Hani Baragwanath Academic Hospital, University of the WitwatersrandSanofi-Aventis South Africa (Pty) LtdSanofi-Aventis South Africa (Pty) LtdSanofi-Aventis South Africa (Pty) LtdGlucose clamp studies form an integral part of the early development of insulin therapies. Data generated in these studies are used to establish pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the agents, but methodological differences confound comparison of results from different glucose clamp studies. The first part of this series on glucose clamp studies discussed practical tips for the interpretation of glucose clamp studies. The second part of the series compares the PK/PD profiles of longer-acting basal analogue insulins, insulin degludec (IDeg) and insulin glargine U300 (Gla-300). The patient populations for glucose clamp studies with these analogue insulins differ, and therefore direct comparison of the data is not always possible. The maximum duration of action of IDeg is reported as 42 h and that of Gla-300 as 36 h, translating to 24 h coverage. The plasma insulin concentration of IDeg is 56 times that of Gla-300. Results from phase III clinical trials for these analogue insulins confirm the predictability and low within-subject variability observed in glucose clamp studies. Insight into the PK/PD profiles of longer-acting basal analogue insulins allows the treating physician to utilise these characteristics to optimise the treatment of their patients with diabetes.https://safpj.co.za/index.php/safpj/article/view/4903analogue insulinsglucose clamptime–action profilepharmacokineticspharmacodynamics |
| spellingShingle | Oppel B.W. Greeff Jacob John van Tonder Kershlin Naidu Alicia McMaster Alet van Tonder Rashem Mothilal A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 South African Family Practice analogue insulins glucose clamp time–action profile pharmacokinetics pharmacodynamics |
| title | A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 |
| title_full | A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 |
| title_fullStr | A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 |
| title_full_unstemmed | A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 |
| title_short | A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300 |
| title_sort | practical guide to the interpretation of pk pd profiles of longer acting analogue insulins part two insulin degludec vs insulin glargine u300 |
| topic | analogue insulins glucose clamp time–action profile pharmacokinetics pharmacodynamics |
| url | https://safpj.co.za/index.php/safpj/article/view/4903 |
| work_keys_str_mv | AT oppelbwgreeff apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT jacobjohnvantonder apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT kershlinnaidu apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT aliciamcmaster apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT aletvantonder apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT rashemmothilal apracticalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT oppelbwgreeff practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT jacobjohnvantonder practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT kershlinnaidu practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT aliciamcmaster practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT aletvantonder practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 AT rashemmothilal practicalguidetotheinterpretationofpkpdprofilesoflongeractinganalogueinsulinsparttwoinsulindegludecvsinsulinglargineu300 |